Benchmark Reiterates Buy on Marvell, $275 Price Target
- Rating
- Buy
- Unchanged
- Target
- $275
- Unchanged
- Outcome
- Reached
- on October 6, 2026

What the analyst said
Benchmark analyst Cody Acree reiterated a Buy rating and $275 price target on Marvell (NASDAQ: MRVL) on August 28, 2026.
“We reiterate our Buy & $275 PT. Marvell fell about 7.5% after hours to $223, broadly matching the expectation reset we outlined in our preview.
The $2.739B/$0.94 Q2 only modestly exceeded Street and the $3.15B/$1.10 Q3 guide was a comparatively measured raise.
In our opinion, that was insufficient against a stock up roughly 28% in one month and 196% in six months, particularly one day after NVIDIA established a much higher AI earnings-season benchmark.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.
Where the price stands
MRVL trades at $171. The 24 analysts who set a target in the last 3 months range from $175 to $433, with a median of $300. This $275 target is 8% below the median.
Since the note MRVL has moved −29% (from $241). 12-month window: day 67 of 365, closes on August 28, 2027.
Track record
This call✓ Target reached on October 6, 2026, 43 days after the note. Same target as this firm’s August 24, 2026 note, so it is scored there.
Firm track recordStoneX: 70% of its 23 targets at least a year old were reached within 12 months (#19 of 26 firms). Accuracy ranking →
StoneX on Marvell
StoneX price targets on Marvell
6 calls from February 3, 2026 to October 7, 2026. The target went from $130 to $375 (+188%). The rating moved from Hold to Buy.




